Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co.,Ltd. (HKG:1349)

Hong Kong flag Hong Kong · Delayed Price · Currency is HKD
3.290
+0.060 (1.86%)
Feb 13, 2026, 4:08 PM HKT
Market Cap8.00B +26.1%
Revenue (ttm)777.75M +2.9%
Net Income-68.49M
EPS-0.08
Shares Out1.04B
PE Ration/a
Forward PEn/a
Dividend0.07 (2.10%)
Ex-Dividend Daten/a
Volume1,346,000
Average Volume2,597,970
Open3.280
Previous Close3.230
Day's Range3.260 - 3.320
52-Week Range2.130 - 5.290
Beta0.13
RSI59.36
Earnings DateMar 31, 2026

About HKG:1349

Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co.,Ltd., engages in the research, development, manufacture, and sale of bio-pharmaceutical products in the People's Republic of China. It offers genetic engineering platform drugs, including Trop2-SN38 ADC that is in Phase III clinical trials for Triple-negative breast cancer; CD30-DM1 antibody-drug conjugate (ADC), which have complected Phase I clinical trials for tumors; Trop2-BB05 ADC that is in Phase I clinical trial for tumors; DLL3-BB05 ADC, which is in phase I clinical trial for tumors; and H... [Read more]

Sector Healthcare
Founded 1996
Employees 899
Stock Exchange Hong Kong Stock Exchange
Ticker Symbol 1349
Full Company Profile

Financial Performance

In 2024, HKG:1349's revenue was 709.40 million, a decrease of -16.61% compared to the previous year's 850.73 million. Earnings were 39.73 million, a decrease of -63.42%.

Financial numbers in CNY Financial Statements